FOI 2024-259

Please note, the following data was obtained from the period 1^st April 2024 - 30^th June 2024:

Q1. Do you treat patients for Urothelial cancer (Yes or No)?  If No, where do you refer patients for treatment

Yes

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

·       Atezolizumab (Tecentriq) - <5

·       Avelumab (Bavencio) - 5

·       Carboplatin single agent or in any other combination - NIL

·       Carboplatin with Gemcitabine - 9

·       Carboplatin with Paclitaxel - NIL

·       Cisplatin single agent or in any other combination - NIL

·       Cisplatin with Gemcitabine - <5

·       Cisplatin with Gemcitabine + Nivolumab (Opdivo) - NIL

·       Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) - NIL

·       Nivolumab (Opdivo) - NIL

·       Pembrolizumab (Keytruda) - NIL

·       Other active systemic anti-cancer therapy - <5

·       Palliative care only - <5

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

No, the Trust does not currently have any research studies in this field.

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

·       Atezolizumab (Tecentriq) - 7

• Atezolizumab in combination with Bevacizumab, Carboplatin and Paclitaxel - <5

·       Durvalumab (Imfinzi) - 9

·       Nivolumab (Opdivo) - <5

·       Pembrolizumab (Keytruda) - NIL

·       Chemotherapy - 9

·       Radiotherapy - This service is not offered at ELHT.

·       Chemotherapy AND Radiotherapy - Radiology services are not offered at ELHT.